Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin plus hypothermia for neonatal hypoxic ischaemic encephalopathy
ACTRN12614000669695Phase 3Completed
- Sponsor
- University of Sydney
- Start
- May 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) comparing Epoetin alfa + therapeutic hypothermia with Placebo saline + therapeutic hypothermia (2 arms). Primary endpoint: Composite of death or moderate/severe disability. Started May 2016; status: completed.
02
Drugs
epoetin alfa
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on ACTRN12614000669695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000669695.